Amyotrophic lateral sclerosis accelerating treatments and improving quality of life : proceedings of a workshop--in brief
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. No present treatments can stop or reverse the disease, although Food and Drug Administration (FDA)-approved formulations may extend life by several months. As part of the information-gathering phase...
| Main Author: | |
|---|---|
| Corporate Authors: | , , , |
| Other Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Washington, DC
National Academies Press
2023, November 2023
|
| Series: | Proceedings of a workshop--in brief
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. No present treatments can stop or reverse the disease, although Food and Drug Administration (FDA)-approved formulations may extend life by several months. As part of the information-gathering phase of a study on ALS, the National Academies Board on Health Care Services and Board on Health Sciences Policy cohosted a virtual public workshop series in August and September 2023 to identify key actions for the public, private, and nonprofit sectors to undertake to make ALS a livable disease within a decade. Speakers explored topics including access to high-quality, evidence-based ALS care, the lived experience of ALS, and ALS research and therapeutic development. This publication summarizes the presentations and discussion of the workshop |
|---|---|
| Physical Description: | 1 PDF file (14 pages) |
| ISBN: | 9780309713146 0309713145 |